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Introduction
In chronic inflammation, which leads to tissue destruction
and fibrosis, immunocompetent cells migrate through the
vascular endothelium to the target tissue. A prototype of
these events is synovitis, which occurs in diseases such as
rheumatoid arthritis. The hypothesis that cells from the
bone marrow could also migrate directly to the synovium
through channels interconnecting the two compartments is
still under debate. Also, there is no definitive answer
regarding the number of cells that result from infiltration of
the synovium after migration, or from proliferation at the
local site. Furthermore, the survival of the cells in synovitis
is being subjected to some scrutiny, because there is some
evidence for a lack of apoptosis in pathological conditions.
The interaction between lymphocytes of different subsets
and monocyte/macrophages (type A synovial cells) results in
the production of proinflammatory cytokines. These include
interleukin (IL)-1 and tumour necrosis factor (TNF)-a,
which induce connective tissue cells (type B synovial cells or
synoviocytes) to produce large amounts of matrix metallo-
proteinases (MMPs), which in turn degrade extracellular
matrix components (eg collagens and proteoglycans).
Simultaneously, counter-regulatory mechanisms (cytokine
inhibitors, anti-inflammatory cytokines and protease
inhibitors) are triggered in an attempt to block inflamma-
tion and tissue destruction. During, and shortly after the
onset of synovitis chondrocytes and bone-derived cells
(osteoblasts and osteoclasts) are activated by the same
cytokines, together with prostanoids [mainly prostaglandin
E2 (PGE2)], to degrade the extracellular matrix via MMPs
and to remove the mineral phase of the bone. The inflam-
matory and destructive process is often followed by
attempts at repair which, unfortunately, result mostly in
fibrosis and nonfunctional tissue. The role of cytokines
(eg TNF-a and IL-1), growth factors and tissue destruc-
tion has been extensively reviewed, and, owing in particu-
lar to the concept of inhibition of TNF-a, crucial advances
in therapeutic intervention have been made [1,2].
Proinflammatory and anti-inflammatory
cytokines
The research of the past few years has mostly focused on
soluble factors [mainly proinflammatory and anti-inflam-
matory cytokines derived from T helper (Th)1, Th2 or
Th3] as well as on growth factors and angiogenic factors,
and more recently cytokines such as IL-15, IL-16, IL-17
and IL-18 were analyzed in depth in the context of synovi-
tis. IL-15 plays a proinflammatory role in rheumatoid
arthritis by inducing cell migration and the production of
TNF-a [3]. IL-16 released by tissue-infiltrating CD8+ T
cells in rheumatoid synovitis influences the anti-inflamma-
tory activity by inhibiting the production of interferon-g,
IL-1b and TNF-a in synovium [4]. IL-17 secreted by
CD4+-activated memory T cells induces nuclear factor-kB,
IL-6, IL-8, granulocyte–macrophage colony-stimulating
factor (GM-CSF) and PGE2 production by human fibrob-
lasts and acts synergistically with TNF-a and IL-1 [5,6].
IL-18, together with IL-12 or IL-15, induces significant
interferon-g production by synovial tissue in vitro, TNF-a
synthesis by CD14+ macrophages in synovial culture, and
promotes GM-CSF and nitric oxide production. IL-18 is
upregulated by TNF-a and IL-1b and promotes Th1 cell
development in synovial membrane. In collagen-induced
arthritis in a murine model [7], IL-18 facilitates the devel-Arthritis Research    Vol 1 No 1 Dayer and Burger
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opment of erosive, inflammatory arthritis. The role of IL-
18 is complex, however, and it can also act as an inhibitor of
osteoclast formation; this process is contact dependent [8].
IL-18 produced by osteoblastic stromal cells inhibits osteo-
clast formation in murine haematopoietic and primary
osteoblast stromal cells. This action is mediated via GM-
CSF production, and not interferon-g, because neutralizing
antibodies to GM-CSF were able to rescue IL-18-induced
inhibition of osteoclastogenesis. The elevated levels of IL-
18 production in osteoblastic cells appear to correlate with
cells at a more differentiated stage. Thus, IL-18 production
by mature osteoblasts may be one of the mechanisms that
limit osteoclast formation by these cells. By counteracting
IL-1, IL-18 may regulate bone homeostasis.
Proteases and prodestructive cytokines
It was not until recently that the role of direct contact
between cells was studied more systematically [9]. Even
in severe diseases, in which the activation and interaction
of circulating blood cells such as monocytes and lympho-
cytes might be expected, it is very difficult to demonstrate
that cell–cell contact is direct and that it leads to the pro-
duction of cytokines or MMPs in the blood stream. This is
illustrated by the difficulty in measuring circulating pro-
inflammatory cytokines such as IL-1 and TNF-a, even if
their abundance is clearly established at the local inflam-
matory site. However, as soon as the inflammatory cells
have migrated to the tissue, it is likely that, in addition to
the role of soluble products, direct cell contact prompts
the release of inflammatory mediators and proteolytic
enzymes. This suggests that many molecules, mostly large
macromolecules, present in the plasma prevent cell–cell
contact. These molecules may occur in much lesser con-
centrations, or be absent in the interstitial tissue, thus per-
mitting cell–cell contact.
Many investigators have advanced sound arguments for T
lymphocytes playing a pivotal role in the pathogenesis of
synovitis, at least at some stage of the disease. In rheuma-
toid arthritis, T lymphocytes that display a mature helper
phenotype are the main infiltrating cells in the synovium,
accounting for 16% of total cells in ‘transitional areas’ and
for 75% in lymphocyte-rich areas. Extravasation of T lym-
phocytes occurs at the level of high endothelial venules.
In the perivascular space, activated T lymphocytes bind to
matrix proteins. They are in close contact with monocytes,
and also with synoviocytes at a more advanced stage of the
disease. The T-cell population in inflamed synovial tissue
belongs predominantly to the Th1 subset [10]. Interest-
ingly, these T cells show a marked staining for the
chemokine receptors CCR5 and CXCR3, and are only
occasionally positive for CCR3. It appears that CCR5 is
highly expressed on Th1 cells and is rarely present in Th2
cells, whereas CCR3 is found in Th2 cells but not in Th1
cells and CXCR3 is highly expressed in both T-cell
subsets. MIP-1b appears to be a selective ligand for
CCR5, eotaxin is a ligand for CCR3, and IP-10 is a ligand
for CXCR3.
Importance of cell contact
The importance of cell contact, and not only soluble factors,
has been emphasized in  transgenic mice expressing T cell-
targeted membrane-associated human mutant TNF-a,
which displayed proliferative synovitis and chronic inflam-
matory arthritis [11]. This suggests that at least part of the
pathogenic activity of T cells in vivo may be due to the
expression of the membrane-associated form of TNF-a by
T lymphocytes. In addition to T cells, macrophage-derived
cells play a crucial part, and indeed a positive correlation
was established between CD14 cell counts of both lining
and sublining CD68 cells and articular destruction [12].
Thus, many observations suggest that both T cells and
macrophages are important and that contact between T
cells and macrophages, or even synoviocytes of the fibrob-
last lineage, in the pannus may be involved in the patho-
genesis of inflammatory destructive arthritis. Other cells
may play an important role in the onset of the inflammatory
process, such as mast cells, which are often associated with
the production of TNF-a and IL-1b by adjacent cells,
especially at sites of cartilage erosion [13].
The activation of effector cells mediated by T lymphocytes
has been well documented by the induction of B-cell pro-
duction and antibody secretion, both requiring direct
cell–cell contact and soluble factors. The claim that autoan-
tibodies induce arthritis has recently been challenged [14].
Therefore, similar to the direct contact between T and B
cells, the T cell–monocyte interaction occurs as shown in
experimental systems. Surface molecules involved in the
T-cell signalling of monocyte/macrophages by direct
contact is being investigated and has resulted in the obser-
vation that this contact leads to the production of IL-1 and
TNF-a by monocytes, and more markedly after differentia-
tion into macrophages by 1,25-dihydroxyvitamin D3 [15,16].
This has been further illustrated in terms of specificity,
because IL-10 is not produced in a similar system [17].
Membrane-associated cytokines such as TNF and IL-1, and
other surface molecules, could activate monocyte/
macrophages upon contact with stimulated T cells. The
cooperation between activated monocyte/macrophages and
interferon-g-secreting CD4 helper (Th1) cells is controlled
by two categories of molecules: cell-surface molecules
including major histocompatibility complex antigen, B7.1/2,
lymphocyte-function-associated antigen (LFA3), LFA1,
CD40 on macrophage, and T cell receptor, CD28, cytotoxic
T-lymphocyte-associated antigen-4, CD2, intercellular
adhesion molecule-1, CD40L on Th1 cells. During the
course of this interaction, Th1 cells produce IL-2 and IL-17,
which act on T cells in an autocrine or paracrine fashion, andhttp://arthritis-research.com/26oct99/ar0101c04
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interferon-g, which acts on the interferon-g receptor on
macrophages. In turn, macrophages produce IL-1 and TNF,
which also act in an autocrine fashion but, more important,
on other target cells in the synovium. A great deal of atten-
tion is being paid to CD40/CD40L, which is involved in the
contact activation of both human and murine
monocyte/macrophages by T lymphocytes stimulated for a
short period [18,19]. Furthermore, peripheral blood T lym-
phocytes isolated from CD40L-knockout mice and stimu-
lated for a short period failed to induce monocyte activation.
In contrast, when stimulated for a longer period, T lympho-
cytes isolated from both CD40L-knockout and wild-type
mice triggered monocyte activation, but to a lower extent
[20]. An argument against the predominant role of
CD40/CD40L is the fact that the most effective human T-
cell line for inducing signalling of monocytes by direct
contact (human lymphocytic cell line HUT-78) does not
express CD40L messenger RNA, whether in resting or acti-
vated conditions. This suggests that CD40/CD40L might be
involved in contact-activation of monocyte/macrophages by
T lymphocytes stimulated for short periods of time, but not
for long periods, the latter cells by then no longer expressing
CD40L.
Specific cell-surface molecules involved in IL-1
and TNF production
One study [21] has shown that functional CD40L was
expressed by T lymphocytes from the synovial fluid of
rheumatoid arthritis patients. Although immunohisto-
chemical analysis of synovial tissue demonstrated CD40L
expression in infiltrating cells of the vascular/perivascular
area, no staining was observed in infiltrating cells that
migrated farther [22]. These results suggest that CD40L
may be predominantly involved in the extravasation of T
lymphocytes into the pannus through the vascular
endothelium, but have less involvement in IL-1/TNF and
MMP production. The study also implies that cell-surface
factors other than CD40L were involved in T lymphocyte
contact-signalling of monocytes. The general conclusion
to be drawn is that, depending on the timing and conse-
quently the stage of the immunoinflammatory condition,
different molecules could be used for similar functions,
and these points have to be taken into consideration for
therapeutic intervention. Other studies [23] have shown
that cytokine production was induced in monocytes by
soluble CD23. Our studies [17] have shown that LFA-1
(CD11a/CD18) and CD69 play a role in the activation of
human monocytic cells by stimulated T cells [17]. Anti-
bodies to CD11a, CD11b, CD11c and CD69 partially
inhibited the activity of contact-activation factors. The
latter data were recently confirmed by a study [24] that
showed that IL-15 induced synovial T cells from rheuma-
toid arthritis patients to activate the production of TNF-a
by macrophages. This effect was inhibited by antibodies
to CD69, LFA-1 and intercellular adhesion molecule-1.
Antibodies to known cell-surface antigens (CD2, CD11a,
CD11b, CD11c, CD14, CD18, CD23, CD29, CD40,
CD40L, CD54, CD69, cytotoxic T-lymphocyte associated
antigen-4, CD95, CD95L) or membrane-associated
cytokines (interferon-g, IL-2, GM-CSF, IL-1, TNF-a,
leukotrienes), and cytokine inhibitors (IL-1 receptor
antagonist, TNF soluble receptors) failed to abolish the
activity of contact-activation factors in monocytes [9].
Thus, it is possible that some already identified surface
molecules are involved in T-cell-signalling of monocyte/
macrophages. Inhibitors (eg antibodies) to these mole-
cules fail to abolish monocyte activation altogether,
however, suggesting that the required factor(s) for T-cell-
signalling of human monocytes by direct contact remain(s)
to be identified.
Balance between IL-1/IL-1 receptor antagonist
and MMPs/TIMP
Subcellular fractionation showed that the activation
factors are located in the plasma membranes of stimu-
lated T cells. T-cell clones expanded from a single
healthy blood donor express surface factors that activate
monocyte/macrophages, but to varying extents. Interest-
ingly, the products that are induced in the target cell
differ depending on the nature of the stimulating agent
and the time of stimulation of T lymphocytes. This could
imply that several contact-activation factors, probably
acting synergistically, are expressed on the surface of
stimulated T lymphocytes in a hierarchy that varies
depending on the type and time of activation. The T-cell
subsets are important because Th1 clones that preferen-
tially express CCR5 are, because of cell–cell contact,
potent inducers of IL-1b and TNF-a on macrophages
while inducing virtually no IL-1 receptor antagonist,
whereas Th2 clones induce large amounts of IL-1 recep-
tor antagonist and almost no IL-1b [25]. Plasma cell mem-
branes from antigen-activated Th1 and Th2 clones also
proved to be potent inducers of MMP-1 production by a
human monocytic cell line, whereas tissue inhibitor of
metalloproteinase (TIMP)-1 levels were not affected.
Using neutralizing reagents, cell membrane-associated
TNF was found to be partially involved in this MMP-1
induction by both Th1 and Th2 cells.
During advanced chronic inflammation, stimulated T lym-
phocytes can also potentially contact cells other than
mononuclear phagocytes that are involved in pathogenesis.
Such target cells include synoviocytes. Indeed, upon contact
with membranes of stimulated T lymphocytes, synoviocytes
produce large amounts of MMP-1 and PGE2, but no TIMP-
1 [26]. The surface factors involved in contact activation of
synoviocytes have been identified as membrane-associated
cytokines, mainly TNF-a and IL-1a. These cytokines are
not involved in the activation of monocyte/macrophages by
T-cell membranes. It is therefore intriguing that T lympho-
cytes should have developed different cell-signalling
systems adapted to the different target cells.Arthritis Research    Vol 1 No 1 Dayer and Burger
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Conclusion
Current experimental results strongly suggest that by
direct cell–cell contact, membranes of stimulated T lym-
phocytes attracted by specific chemokines potentiate the
inflammatory response. They do so by favouring the
extravasation of cells from the immune system into the
target tissue through the endothelium, and by activating
the production of proinflammatory cytokines and MMPs at
inflammatory sites (ie by stimulating monocytes and syn-
oviocytes). This mechanism (cell–cell contact with stimu-
lated T lymphocytes) induces an unbalanced production of
MMPs and TIMP-1 in vitro and may lead to tissue destruc-
tion  in vivo. We thus hypothesize that cell–cell contact
between stimulated T lymphocytes and surrounding cells
represents an important mechanism that contributes to the
pathogenesis of inflammation and tissue destruction in
chronic inflammatory diseases such as rheumatoid arthritis.
Despite the impressive clinical results obtained with anti-
TNF therapy, approximately 25% of the patients seem to
be resistant. This hints at the possibility that, during the
course of the disease, other important mechanisms trigger
synovitis and tissue destruction. In addition to newly
described interleukins (IL-15, IL-17, IL-18), some of the
mechanisms could involve direct contact between stimu-
lated T cells and macrophages or synoviocytes. If partly
induced by TNF-a, the production of IL-1 can also be
triggered by mechanisms independent of TNF, and the
production of MMPs is not solely induced by TNF. It is
therefore likely that therapeutic intervention will have to
aim at additional cytokines and direct cellular contact to
block fully the pathogenesis of rheumatoid arthritis.
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